Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study

Chan Shen, A. Dasari, Y. Xu, Shouhao Zhou, D. Gu, Y. Chu, D. M. Halperin, Y. T. Shih, J. C. Yao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients’ conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8% vs. 53.3%), abdominal pain (22.2% vs. 7.6%), heart failure (11.7% vs. 8.0%), diarrhea (5.8% vs. 1.8%), peripheral edema (5.4% vs. 3.8%) and irritable bowel syndrome (1.2% vs. 0.5%) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean: 22.1 vs. 17.2), percentage with ER visits (20.9% vs. 11.6%), and hospitalizations (28.4% vs. 17.0%). Similarly, NET patients incurred significantly higher total (mean: $14602 vs. $9464), outpatient (mean: $5987 vs. $4253), and inpatient costs (mean: $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.

Original languageEnglish (US)
Article number16863
JournalScientific reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Neuroendocrine Tumors
Medicare
Epidemiology
Databases
Delivery of Health Care
Costs and Cost Analysis
Outpatients
Irritable Bowel Syndrome
Prednisolone
Abdominal Pain
Inpatients
Diarrhea
Edema
Hospitalization
Heart Failure
Hypertension
Control Groups
Incidence
Population

All Science Journal Classification (ASJC) codes

  • General

Cite this

Shen, Chan ; Dasari, A. ; Xu, Y. ; Zhou, Shouhao ; Gu, D. ; Chu, Y. ; Halperin, D. M. ; Shih, Y. T. ; Yao, J. C. / Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors : A SEER-Medicare Database Study. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{9050cab4325a47b393ee45e9fbe4b071,
title = "Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study",
abstract = "The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients’ conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8{\%} vs. 53.3{\%}), abdominal pain (22.2{\%} vs. 7.6{\%}), heart failure (11.7{\%} vs. 8.0{\%}), diarrhea (5.8{\%} vs. 1.8{\%}), peripheral edema (5.4{\%} vs. 3.8{\%}) and irritable bowel syndrome (1.2{\%} vs. 0.5{\%}) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean: 22.1 vs. 17.2), percentage with ER visits (20.9{\%} vs. 11.6{\%}), and hospitalizations (28.4{\%} vs. 17.0{\%}). Similarly, NET patients incurred significantly higher total (mean: $14602 vs. $9464), outpatient (mean: $5987 vs. $4253), and inpatient costs (mean: $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.",
author = "Chan Shen and A. Dasari and Y. Xu and Shouhao Zhou and D. Gu and Y. Chu and Halperin, {D. M.} and Shih, {Y. T.} and Yao, {J. C.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-35340-4",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors : A SEER-Medicare Database Study. / Shen, Chan; Dasari, A.; Xu, Y.; Zhou, Shouhao; Gu, D.; Chu, Y.; Halperin, D. M.; Shih, Y. T.; Yao, J. C.

In: Scientific reports, Vol. 8, No. 1, 16863, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors

T2 - A SEER-Medicare Database Study

AU - Shen, Chan

AU - Dasari, A.

AU - Xu, Y.

AU - Zhou, Shouhao

AU - Gu, D.

AU - Chu, Y.

AU - Halperin, D. M.

AU - Shih, Y. T.

AU - Yao, J. C.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients’ conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8% vs. 53.3%), abdominal pain (22.2% vs. 7.6%), heart failure (11.7% vs. 8.0%), diarrhea (5.8% vs. 1.8%), peripheral edema (5.4% vs. 3.8%) and irritable bowel syndrome (1.2% vs. 0.5%) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean: 22.1 vs. 17.2), percentage with ER visits (20.9% vs. 11.6%), and hospitalizations (28.4% vs. 17.0%). Similarly, NET patients incurred significantly higher total (mean: $14602 vs. $9464), outpatient (mean: $5987 vs. $4253), and inpatient costs (mean: $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.

AB - The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients’ conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8% vs. 53.3%), abdominal pain (22.2% vs. 7.6%), heart failure (11.7% vs. 8.0%), diarrhea (5.8% vs. 1.8%), peripheral edema (5.4% vs. 3.8%) and irritable bowel syndrome (1.2% vs. 0.5%) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean: 22.1 vs. 17.2), percentage with ER visits (20.9% vs. 11.6%), and hospitalizations (28.4% vs. 17.0%). Similarly, NET patients incurred significantly higher total (mean: $14602 vs. $9464), outpatient (mean: $5987 vs. $4253), and inpatient costs (mean: $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.

UR - http://www.scopus.com/inward/record.url?scp=85056649398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056649398&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-35340-4

DO - 10.1038/s41598-018-35340-4

M3 - Article

C2 - 30442902

AN - SCOPUS:85056649398

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16863

ER -